MGNX — MACROGENICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1125345 ·
Last close
$4.33
Market Cap
$275.23M
52W High
$5.08
52W Low
$2.85
ADV30
1,078,747
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,775,000 | 11,245,000 | -33,439,000 | -36,774,000 | 217,873,000 | 66,517,000 | 196,675,000 |
| Dec 2025 | 41,227,000 | 31,112,000 | -12,097,000 | -14,155,000 | 256,846,000 | 57,217,000 | 201,255,000 |
| Sep 2025 | 72,839,000 | 61,250,000 | 18,636,000 | 16,822,000 | 270,763,000 | 80,129,000 | 203,762,000 |
| Jun 2025 | 22,241,000 | 13,335,000 | -36,758,000 | -36,251,000 | 245,416,000 | 130,686,000 | 198,798,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,961,000
Investing CF
$-78,681,000
Financing CF
$69,589,000
CapEx
$-1,729,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.53
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,281,112,000
Inventory
$9,498,000
Receivables
$10,425,000
ST Investments
$87,712,000
EBIT TTM
$-57,725,000
Pretax Income TTM
$-71,030,000
Interest Exp TTM
$13,305,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$157,083,008
EBITDA
$-56,568,000
Free Cash Flow
$10,108,750
Enterprise Value
$172,763,472
Total Cash
$154,228,992
Total Debt
$36,509,000
Shares Out
63,563,123
Trailing EPS
$-1.11
Book Value
$0.33
ROE
-140.3%
ROA
-18.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 149,500,000 | -72,841,000 | -74,620,000 | 256,846,000 | 201,255,000 | — | -81,040,000 |
| Dec 2024 | 149,962,000 | -110,578,000 | -66,966,000 | 261,655,000 | 145,598,000 | — | -68,373,000 |
| Dec 2023 | 58,749,000 | -168,244,000 | -9,058,000 | 298,418,000 | 145,805,000 | — | -78,205,000 |
| Dec 2022 | 150,018,000 | -121,418,000 | -119,758,000 | 280,468,000 | 138,455,000 | — | -86,959,000 |
TTM Snapshot
Revenues TTM
$178,501,000
NetIncome TTM
$-3,836,000
OpCashFlow TTM
$0
Assets (Latest)
$261,655,000
Forward EPS
$-1.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRE | Prenetics Global Ltd | $275.39M | $17.86 | — |
| RNAC | Cartesian Therapeutics, Inc. | $277.95M | $9.46 | — |
| TTRX | Turn Therapeutics Inc. | $281.20M | $9.44 | — |
| TRDA | Entrada Therapeutics, Inc. | $268.64M | $6.92 | — |
| GALT | GALECTIN THERAPEUTICS INC | $267.38M | $4.06 | — |
News headlines (Yahoo Finance, 1h cache)
R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy
2026-07-05 22:52 · Yahoo
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
2026-07-02 22:40 · Yahoo
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
2026-07-02 16:00 · Yahoo
Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations
2026-07-02 15:00 · Yahoo
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
2026-07-02 13:25 · Yahoo
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
2026-06-22 20:43 · Yahoo
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
2026-06-15 16:12 · Yahoo
How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks
2026-06-07 00:18 · Yahoo
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
2026-05-28 22:33 · Yahoo
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
2026-05-28 16:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.